Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 993.

https://doi.org/10.1182/blood.V114.22.993.993

Published: 2009

Journal Articles

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, B. Nebiyou Bekele, PhD, Elias Jabbour, MD, Farhad Ravandi, M.D., Hui Yang, MD, PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Jorge Cortes, MD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Sherry Pierce, RN, Jan A. Burger, MD, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Deborah Thomas, Willie Newsome, RN, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1055.

https://doi.org/10.1182/blood.V114.22.1055.1055

Published: 2009

Journal Articles

Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study

Ayalew Tefferi, MD, Srdan Verstovsek, Giani Barosi, Francesco Passamonti, MD, Gail J. Roboz, MD, Heinz Gisslinger, Ronald Paquette, MD, Francisco Cervantes, MD, Candido E. Rivera, MD, H. Joachim Deeg, Juergen Thiele, Hans Michael Kvasnicka, James W. Vardiman, MD, B. Nebiyou Bekele, PhD, Ruben A. Mesa, MD, FACP, Robert P Gale, Hagop M Kantarjian

Blood (2008) 112 (11): 663.

https://doi.org/10.1182/blood.V112.11.663.663

Published: 2008

Journal Articles

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

Vince D. Cataldo, M.D., Michael A. Thompson, M.D., PhD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, B. Nebiyou Bekele, PhD, Camilo Jimenez, M.D., William A. Murphy, M.D., Auris O. Huen, Pharm.D., Rebecca B. Arbuckle, Pharm.D., Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Nathan Fowler, M.D., Larry W. Kwak, M.D., Peter W. McLaughlin, M.D., Sattva S. Neelapu, M.D., Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, M.D., Fredrick B. Hagemeister, M.D.

Blood (2008) 112 (11): 5297.

https://doi.org/10.1182/blood.V112.11.5297.5297

Published: 2008

Journal Articles

Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD.

Michael A. Thompson, MD, PhD, Tapan M. Kadia, MD, B. Nebiyou Bekele, PhD, Michael Wang, MD, Jorge E. Romaguera, MD

Blood (2007) 110 (11): 1581.

https://doi.org/10.1182/blood.V110.11.1581.1581

Published: 2007

Journal Articles

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Deborah Blamble, PHDP, B. Nebiyou Bekele, PhD, Miloslav Beran, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jan Burger, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 2840.

https://doi.org/10.1182/blood.V110.11.2840.2840

Published: 2007

Journal Articles

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Kathleen A. Sobocinski, MS, Peter F. Thall, PhD, B. Nebiyou Bekele, PhD, John P. Klein, PhD, Shari Lennon, Mary M. Horowitz, MS, MD, Borje Andersson, MD, PhD

Blood (2004) 104 (11): 349.

https://doi.org/10.1182/blood.V104.11.349.349

Published: 2004

Journal Articles

Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.

Charles Asa Koller, MD, B. Nebiyou Bekele, PhD, Xian Zhou, PhD, Charles Park, BS, Zeef Estrove, MD, Susan O’Brien, MD, Michael Keating, MD, Iman Jilani, PhD, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Maher Albitar, MD

Blood (2004) 104 (11): 1905.

https://doi.org/10.1182/blood.V104.11.1905.1905

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study

Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid

Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD.

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation.

Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology